Results 31 to 40 of about 18,311 (150)

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer

Science Advances, 2023
Accurate predictive biomarkers of response to immune checkpoint inhibitors (ICIs) are required for better stratifying patients with cancer to ICI treatments.
Bar Kaufman, Orli Abramov, Anna Ievko, Daria Apple, M. Shlapobersky, I. Allon, Yariv Greenshpan, Baisali Bhattachrya, Ofir Cohen, Tatiana Charkovsky, Alexandra Gayster, R. Shaco-levy, K. Rouvinov, A. Livoff, M. Elkabets, A. Porgador   +15 more
semanticscholar   +1 more source

Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma.

Clinical Cancer Research, 2022
PURPOSE Immune checkpoint inhibitors combined with anti-angiogenic agents produce benefits in the treatment of advanced hepatocellular carcinoma (HCC).
R. Esteban-Fabró, Catherine E. Willoughby, M. Piqué-Gili, C. Montironi, J. Abril-Fornaguera, J. Peix, L. Torrens, A. Mesropian, U. Balaseviciute, F. Miró-Mur, V. Mazzaferro, R. Pinyol, J. Llovet   +12 more
semanticscholar   +1 more source

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway

Journal for ImmunoTherapy of Cancer, 2023
Background GLI-similar 1 (GLIS1) is one of of Krüppel-like zinc finger proteins, which are either stimulators or inhibitors of genetic transcription. Nevertheless, its effects on T cell were elusive.
D. Rong, Yuliang Wang, Li Liu, H. Cao, Tian Huang, Hanyuan Liu, Xiaopei Hao, Guangshun Sun, Guoqiang Sun, Zhiying Zheng, Junwei Kang, Yongxiang Xia, Ziyi Chen, Weiwei Tang, Xuehao Wang   +14 more
semanticscholar   +1 more source

Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma

Cancer Cell International
Immunotherapy combined with molecular targeted therapy is increasingly popular in patients with advanced hepatocellular carcinoma (HCC). However, immune-related adverse events(irAEs) brought on by immunotherapy increase the likelihood of side effects ...
Guoqiang Sun, Chuan Liu, Zhengqing Lu, Jinyu Zhang, H. Cao, Tian Huang, Mingrui Dai, Hanyuan Liu, Tingting Feng, Weiwei Tang, Yongxiang Xia   +10 more
semanticscholar   +1 more source

Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients

Cancer Immunology and Immunotherapy
The response rate of anti-PD1 therapy is limited, and the influence of anti-PD1 therapy on cancer patients is unclear. To address these challenges, we conducted a longitudinal analysis of plasma proteomic changes with anti-PD1 therapy in non-small cell ...
Q. Tan, Ruyun Gao, Xiaomei Zhang, Jianliang Yang, P. Xing, Sheng Yang, Dan Wang, Guibing Wang, Shasha Wang, Jiarui Yao, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiaohong Han, Yuankai Shi   +14 more
semanticscholar   +1 more source

Cancer stem cell-derived extracellular vesicles preferentially target MHC-II–macrophages and PD1+ T cells in the tumor microenvironment

PLoS ONE, 2023
Immunotherapy is an approved treatment option for head and neck squamous cell carcinoma (HNSCC). However, the response rate to immune checkpoint blockade is only 13% for recurrent HNSCC, highlighting the urgent need to better understand tumor-immune ...
P. González-Callejo, Zihan Guo, T. Ziglari, N. Claudio, Kayla Hoang Nguyen, N. Oshimori, J. Seras-Franzoso, F. Pucci   +7 more
semanticscholar   +1 more source

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer

Nature Communications, 2021
Only a subgroup of triple-negative breast cancer (TNBC) responds to immune checkpoint inhibitors (ICI). To better understand lack of response to ICI, we analyze 681 TNBCs for spatial immune cell contextures in relation to clinical outcomes and pathways ...
Dora Hammerl, J. Martens, M. Timmermans, M. Smid, A. Trapman-Jansen, R. Foekens, O. Isaeva, L. Voorwerk, H. E. Balcioglu, R. Wijers, I. Nederlof, R. Salgado, H. Horlings, M. Kok, R. Debets   +14 more
semanticscholar   +1 more source

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Nature Medicine, 2019
Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized.
David Liu, B. Schilling, Derek Liu, A. Sucker, E. Livingstone, Livnat Jerby-Arnon, L. Zimmer, R. Gutzmer, I. Satzger, C. Loquai, S. Grabbe, N. Vokes, Claire A. Margolis, J. Conway, M. X. He, Haitham A. Elmarakeby, Felix Dietlein, Diana Miao, A. Tracy, H. Gogas, S. Goldinger, J. Utikal, C. Blank, R. Rauschenberg, D. von Bubnoff, A. Krackhardt, B. Weide, S. Haferkamp, F. Kiecker, B. Izar, L. Garraway, A. Regev, K. Flaherty, A. Paschen, E. V. Van Allen, D. Schadendorf   +35 more
semanticscholar   +1 more source

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

Frontiers in Cell and Developmental Biology, 2020
In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as accomplices to help tumors resist to immunity-induced apoptosis and promote tumor progression.
Q. Lei, Dan Wang, K. Sun, Liping Wang, Yi Zhang   +4 more
semanticscholar   +1 more source

Apoptotic Vesicles Modulate Endothelial Metabolism and Ameliorate Ischemic Retinopathy via PD1/PDL1 Axis

Advanced Healthcare Materials
Pathological angiogenesis with subsequent disturbed microvascular remodeling is a major cause of irreversible blindness in a number of ischemic retinal diseases.
Yutong Jing, Wanmin Zhao, Ziyi Zhou, Wenzhe Wang, Yali Niu, Xiaoning He, Tianfang Chang, Changmei Guo, Bei Li, Guorui Dou   +9 more
semanticscholar   +1 more source